* CV Therapeutics Inc., of Palo Alto, Calif., said underwriters exercised an overallotment option to purchase 275,000 more shares of stock granted in connection with the company's public offering of 2.3 million shares at $8.25 per share. The company raised a total of $21.24 million in the offering. Underwriters were J.P. Morgan Securities Inc., UBS Securities LLC and Invemed Associates Inc., all of New York. (See BioWorld Today, Jan. 23, 1998, p. 1.)
* Progenitor Inc., of Menlo Park, Calif., discovered a human gene involved in angiogenesis, the process of blood vessel formation. The gene, called de-1, is active almost exclusively in endothelial cells, a class of cells that contribute to the normal formation and function of blood vessels. Progenitor has targeted the gene and the protein it encodes in a program to develop therapeutics for cancer and cardiovascular disease. The discovery was published in the journal Genes and Development (Vol. 12(2): 21-33, 1998).
* Sequus Pharmaceuticals Inc., of Irvine, Calif., signed an exclusive agreement with Lemery S.A. de C.V., of Mexico City, a wholly owned subsidiary of Gensia Sicor Inc., of San Diego, for marketing and distribution of Amphocil in Mexico and Central America. Amphocil is a lipid-based form of amphotericin B for treatment of systemic fungal infections. It is approved in Mexico for patients who have failed conventional amphotericin B therapy.
* TheraTech Inc., of Salt Lake City, authorized a stock repurchase plan. The company will buy back up to 1 million shares from time to time in the open market or through privately negotiated transactions. Repurchased shares will be used as part of the company's employee benefits plan.
* SynZyme Technologies Inc., of Irvine, Calif., secured two corporate partners in Europe for the commercialization of polynitroxyl albumin (PNA), its nitroxide compound for use in preventing oxidative damage in ischemia and reperfusion indications such as stroke, heart attack and perioperative ischemia, as well as adverse side effects in chemotherapy and radiotherapy. The Central Laboratory Blood Transfusion Service of the Swiss Red Cross has assumed the costs of developing and manufacturing PNA, and has the exclusive manufacturing rights. B. Braun Melsungen AG, of Melsungen, Germany, has been granted exclusive European marketing rights for all indications except ambulatory stroke, and will pay for clinical trials and commercialization of the product.